🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Allogeneic (MSC's) Application to the Burn Wounds

    United Therapeutics Europe Ltd

    Skin Burn Degree Second

    phase 1 mab completed

    1 trial
  2. Allogeneic CD19/BCMA-targeted CAR-γδT cell injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory/Relapsed Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  3. Allogeneic Cardiosphere-Derived Cells (CDCs)

    CAPRICOR THERAPEUTICS, INC.

    Dilated Cardiomyopathy (DCM)

    phase 1 mab active

    1 trial
  4. Allogeneic MSC

    United Therapeutics Europe Ltd

    Mesenchymal Stromal Cells

    phase 1 mab completed

    1 trial
  5. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial
  6. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam Therapeutics

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial
  7. Ampreloxetine

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial
  8. Ampreloxetine <Dose A>

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial
  9. An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

    AstraZeneca AB

    Inflammation, Respiratory

    phase 1 other active

    1 trial
  10. An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial
  11. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial
  12. An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation

    Ferring Pharmaceuticals

    Infertility in women undergoing assisted reproductive technologies (ART)

    phase 1 other active

    1 trial
  13. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagliflozin Tablets 25 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Jardiance (Empagliflozin) 25 mg film-coated tablets, Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein Germany, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Diabetes

    phase 1 other active

    1 trial
  14. An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis

    phase 1 other active

    1 trial
  15. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib Tablets 100 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with Bosulif (bosutinib) 100 mg, Manufactured and Packed by: Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee, Freiburg, Germany, Imported by: Pfizer Brasil Ltda. Rodovia Presidente Castelo Branco, nº32501, km 32.5 CEP 06696-000 – Itapevi – SP, in healthy adult, huma

    Lacuna Pharma Pty Ltd

    myeloid leukemia

    phase 1 other active

    1 trial
  16. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies, Inc. Steinbach, MB R5G 1Z7, Canada, in healthy, adult, human subjects under

    Lacuna Pharma Pty Ltd

    Seasonal affective disorder, Major depressive disorder

    phase 1 other active

    1 trial
  17. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial
  18. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec® (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo – SP, CNPJ: 56.994.

    Lacuna Pharma Pty Ltd

    Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid Leukemia

    phase 1 other active

    1 trial
  19. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with VENVANSE (lisdexamfetamine dimesylate) 70 mg Hard Gelatin Capsule, imported and registered by: Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. Adm. Jaguariúna-SP CNPJ 60.397.775/0001-74 and manufactured by: Patheon Pharmaceuticals Inc. Cincinnati, United States o

    Lacuna Pharma Pty Ltd

    ADHD (Attention Deficit Hyperactivity Disorder), BED (Binge Eating Disorder)

    phase 1 other active

    1 trial
  20. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrexone hydrochloride film-coated tablet, 50 mg, manufactured by Sun Pharmaceutical Industries Limited, India with NALTREXONE GH (naltrexone hydrochloride) film-coated tablets 50 mg, Product of Generic Health Pty Ltd Suite 2, Level 2 19-23 Prospect Street Box Hill, VIC, 3128, Australia, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Alcohol dependence

    phase 1 other active

    1 trial
  21. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial
  22. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fed condition.

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial
  23. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis

    phase 1 other active

    1 trial
  24. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    Axial spondyloarthritis, Crohn’s disease, Ulcerative colitis, Atopic dermatitis, Rheumatoid arthritis, Psoriatic arthritis

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources